Merger called off between Baylor Scott & White and Memorial Hermann

A merger between Memorial Hermann and Baylor Scott & White Health would have combined 68 hospital campuses and more than 1,100 sites of care across 30 Texas counties. (Baylor Scott & White)

The deal is off between Texas healthcare giants Memorial Hermann Health System and Baylor Scott & White Health.

First reported on Tuesday morning, the ending of talks to complete a megamerger came after both systems concluded they were better without it, according to a joint statement.

"Ultimately, we have concluded that as strong, successful organizations, we are capable of achieving our visions for the future without merging at this time," the statement read. "We will continue to seek opportunities for collaboration as two forward-thinking, mission-driven organizations."

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

The merger, first announced in October, would have combined 68 hospital campuses and more than 1,100 sites of care across 30 Texas counties. 

RELATED: Baylor, Scott & White Health, Memorial Hermann Health System announce merger

It also would have accounted for more than 10 million patient encounters each year, more than $14 billion in combined revenue and more than 14,000 employed and independent physicians and two health plans.

Suggested Articles

A group of House lawmakers want CMMI's mandatory kidney care model to be as narrow as possible and change how it calculates payments.

Humana and Microsoft announced a seven-year strategic partnership to build predictive solutions and intelligent automation to support Humana members.

Humana filed suit Friday against more than a dozen generic drugmakers alleging the companies engaged in price fixing.